CG Oncology, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Revenue | $4.0M | $1.1M | $204,000 |
| Operating income | -$190.8M | -$114.7M | -$55.4M |
| Operating expenses | — | $115.8M | $55.7M |
| Cash from operations | -$132.3M | -$78.7M | -$45.7M |
| Capital expenditure | $134,000 | $234,000 | — |
| Free cash flow | -$132.5M | -$78.9M | — |
| Impairments | $0 | — | — |
| Total assets | $791.6M | $754.8M | $199.3M |
| Total liabilities | $39.0M | $21.4M | $14.5M |
Shares outstanding 88.2M · Free float 89.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.